Gilead Sciences (GILD) Long-Term Debt Repayments (2009 - 2012)
Gilead Sciences' (GILD) quarterly Long-Term Debt Repayments came in at $1.0 billion in Q3 2012, up 2040716.33% quarter-over-quarter from $49000.0 in Q4 2009.
Powered by 
Analysis
Gilead Sciences (GILD) Long-Term Debt Repayments (2009 - 2012) Analysis & Trends
Gilead Sciences (GILD) has reported Long-Term Debt Repayments for 2 consecutive years, with $1.0 billion the latest figure, recorded in Q3 2012.
- For the quarter ending Q3 2012, Long-Term Debt Repayments changed N/A year-over-year to $1.0 billion; the trailing twelve-month figure through Sep 2012 stood at $1.0 billion (up 1388788.89% YoY), and the FY2011 full-year result was $650.0 million, changed N/A from the prior year.
- Long-Term Debt Repayments rose to $1.0 billion in Q3 2012 per GILD's latest filing, from $49000.0 in the prior quarter.
- Across five years, Long-Term Debt Repayments topped out at $1.0 billion in Q3 2012 and bottomed at $23000.0 in Q3 2009.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 212.33 Bn | 198.34 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 180.55 Bn | 177.37 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.28 Bn | 124.42 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.90 Bn | 73.91 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.14 Bn | 55.96 Bn | 1.37 Bn | - |
| 6 | Moderna | 55.12 Bn | 49.98 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.85 Bn | 30.54 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.21 Bn | 29.93 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.89 Bn | 29.89 Bn | 1.16 Mn | - |
| 10 | Insmed | 27.14 Bn | 25.98 Bn | 358.27 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2012 | 1.00 Bn |
| Dec 31, 2009 | 49,000.00 |
| Sep 30, 2009 | 23,000.00 |